menu
    • menu
    [{"orgOrder":0,"company":"Evestia","sponsor":"Cellectar","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2025","type":"Agreement","leadProduct":"CLR 125","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Evestia","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evestia \/ Cellectar","highestDevelopmentStatusID":"5","companyTruncated":"Evestia \/ Cellectar"}]

    Find Clinical Drug Pipeline Developments & Deals by Evestia

    Menu

    Evestia

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Evestia

                            United Kingdom arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Evestia

                            United Kingdom arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CLR 125

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Cellectar

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Cellectar, Evestia Partner for Auger-Emitting Radiopharmaceutical Trial in TNBC

                            Details : Evestia will provide Cellectar with full CRO services for their upcoming Phase 1b study evaluating CLR 125 for the treatment of triple-negative breast cancer (TNBC).

                            Product Name : CLR 125

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Undisclosed

                            September 24, 2025

                            Lead Product(s) : CLR 125

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Cellectar

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth